This is one of my favorites to suggest when you just have that stubborn fat or you are responding to the GLP-1. Most fat loss peptides come with trade-offs. GLP-1 agents cause muscle loss. Full HGH raises blood sugar and IGF-1. CJC/Ipamorelin stacks need careful timing and monitoring. AOD-9604 is one of the cleaner options in the space because it was specifically engineered to do one thing: burn fat — without touching your hormonal axis. WHAT IS IT? AOD-9604 is hGH fragment 176-191. Monash University in Australia isolated the portion of the HGH molecule responsible for lipolysis and built a standalone peptide from it. The key finding from their research: this fragment retains the fat-burning mechanism of growth hormone but does not bind to GH receptors in the liver or muscle. Practically, that means: No effect on blood glucose (confirmed across multiple clinical trials) No effect on IGF-1 No effect on natural GH production It reached Phase 3 clinical trials for obesity treatment. The program was discontinued for commercial reasons — not safety concerns. The safety data from those trials is genuinely solid. HOW IT WORKS AOD-9604 stimulates beta-3 adrenergic receptors on fat cells, triggering the breakdown of stored triglycerides into free fatty acids. The effect is amplified in a fasted state, which is why the standard protocol calls for a morning injection before eating. DOSING 5mg vial + 2.5mL BAC water = 2mg/mL (most common reconstitution) 250mcg = draw to 12.5 IU 300mcg = draw to 15 IU 500mcg = draw to 25 IU Standard dose: 300mcg SubQ in the morning, fasted. Wait 30-60 minutes before eating. Cycle: 12-16 weeks on, 4-6 weeks off. Stacks well with: MK-677 (for muscle preservation), BPC-157, or alongside GLP-1 agents to target fat more specifically while managing the muscle loss problem. BERRY’s EXPERIENCE “AOD-9604 doesn't feel like anything — there's no stimulant effect, no noticeable shift in energy or appetite. The results appear in the mirror over weeks. I ran it at 300mcg/day for 12 weeks combined with a moderate deficit and consistent training. Abdominal fat was the most visibly reduced area, which tracks with the clinical data showing preferential visceral fat loss.”